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Abstract
The Microphthalmia associated transcription factor (Mitf) is an important regulator in melanocyte development and has been
shown to be involved in melanoma progression. The current model for the role of Mitf in melanoma assumes that the total
activity of the protein is tightly regulated in order to secure cell proliferation. Previous research has shown that regulation of
Mitf is complex and involves regulation of expression, splicing, protein stability and post-translational modifications. Here
we show that microRNAs (miRNAs) are also involved in regulating Mitf in melanoma cells. Sequence analysis revealed
conserved binding sites for several miRNAs in the Mitf 39UTR sequence. Furthermore, miR-148 was shown to affect Mitf
mRNA expression in melanoma cells through a conserved binding site in the 39UTR sequence of mouse and human Mitf.I n
addition we confirm the previously reported effects of miR-137 on Mitf. Other miRNAs, miR-27a, miR-32 and miR-124 which
all have conserved binding sites in the Mitf 39UTR sequence did not have effects on Mitf. Our data show that miR-148 and
miR-137 present an additional level of regulating Mitf expression in melanocytes and melanoma cells. Loss of this regulation,
either by mutations or by shortening of the 39UTR sequence, is therefore a likely factor in melanoma formation and/or
progression.
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Introduction
The MITF (Microphthalmia associated transcription factor) protein is a
master regulator of melanocyte development and is important in
several other cell types including the retinal pigment epithelium
(RPE) of the eye, osteoclasts and mast cells [1]. More recently,
MITF was shown to play a role in melanocyte stem cells in the
hair follicle [2]. The Mitf gene encodes a bHLH-Zip transcription
factor of the Myc family [3,4] which regulates melanocyte
differentiation by activating other known melanocyte determi-
nants, including Tyrosinase (Tyr), Tyrosinase-related protein-1
(Tyrp-1) and DCT/Tyrp-2 [5,6]. In addition to regulating
differentiation, MITF is required for melanocyte cell survival
[7,8], proliferation and cell cycle progression [9,10,11,12,13]. The
diverse roles that MITF plays in the development of different cell
types suggests that the expression and function of Mitf must be
highly regulated. In fact, Mitf is regulated at multiple levels,
including transcription, alternative splicing, post-translational
modifications and protein stability. The Mitf gene has at least
nine different promoters, each with a unique 59exon which is
alternatively spliced to the remaining exons 2 through 9 resulting
in several different Mitf isoforms [reviewed in 1]. At the protein
level, MITF is modified post-transcriptionally and has been shown
to be phosphorylated at multiple sites leading to either increase in
transcriptional activation or decrease in protein stability
[14,15,16,17]. In addition, ubiquitination marks MITF for
degradaton [18] and sumoylation has been shown to affect DNA
binding specificity [19,20].
In addition to its essential role in melanocyte development,
expression of Mitf and its target genes is seen in many melanoma
cells [21,22]. Continued expression of MITF has been shown to be
essential for melanoma cell proliferation and survival and, in fact,
MITF has been proposed to act as a lineage survival oncogene in
melanoma [23]. Significantly increased levels of MITF, however,
reduce melanoma cell proliferation and tumorigenicity [24,25].
Consistent with this, there is less MITF expressed in melanoma
cells than in normal melanocytes [25]. Therefore, it has been
proposed that MITF levels dictate functional outcome such that
high levels result in cell cycle arrest and differentiation,
intermediate levels promote proliferation and tumorigenesis
whereas low levels lead to cell cycle arrest and apoptosis.
According to this model, it is extremely important to regulate
MITF expression in melanoma cells.
miRNAs have been proven to be involved in many different cell
processes including cell-cycle regulation, differentiation, prolifer-
ation and apoptosis [reviewed in 26]. miRNAs are thought to
regulate about 30% of coding genes in the human genome and to
date 677 miRNA genes have been discovered in the human
genome and 491 in the mouse (www.microRNA.org) [27].
Misexpression of miRNA genes has been seen in both benign
and malignant cancer and miRNA genes can act as either tumor
suppressors or oncogenes as is seen for the role of coding genes in
cancer progression. Studies have shown that miRNA expression
differs between melanoma cell lines [28] and that miRNA
expression profiles can be used to classify solid tumors in terms
of their differentiation stage and developmental lineage [29]. In an
extensive comparative study on miRNA expression in normal
melanocyte and melanoma cell lines derived from solid tumors
and melanoma metastases, various miRNAs were found to be
differentially regulated in melanoma cells compared to normal
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before. Other miRNAs had been shown to be oncogenic or to
contain tumor suppressive potential in other types of cancer [30].
A few miRNAs have already been linked to Mitf expression.
Bemis et al. (2008) showed that miR-137 downregulates MITF in
melanoma cells [31]. In addition, it has been shown that miR-182
targets Mitf 39UTR sequence in the retina [32], and recently
Segura et al. (2009) showed that miR-182 promotes migration and
survival of melanoma cells by downregulating Mitf expression [33].
Here we study miRNAs with conserved binding sites in the Mitf
39UTR sequence and characterize their effects on Mitf using a
reporter construct. Effects on the endogenous human MITF gene
were also determined in melanoma cells. Our results show that
miRNAs play an important role in regulating MITF mRNA in
melanoma through conserved sites in the 39UTR.
Materials and Methods
PCR amplification of the 39UTR sequence of Mitf
A reporter gene construct was generated which contains the
mouse Mitf-39UTR sequence downstream of the luciferase
reporter gene. The construct was termed mouseMitf-39UTR-
luciferase. To do this, the 39UTR sequence of the mouse Mitf gene
(which is contained in a single exon) was amplified from BAC
clone rpci-23-9a13t7 using Pfu polymerase and the primers
3UTRSacI-Forw: 59-gag ctc cga gcc tgc ctt gct ctg-39 and
3UTRNheI-Rev: 59-gct agc atg tga aaa acc aaa tgc ttt aat ga-39.
The primers included new restriction sites, SacI at the 59end and
NheI at the 39end (underlined bases). The restriction sites were
used for cloning into the Pis0 vector, a Firefly luciferase vector,
modified from the PGL3 Control Vector from Promega by adding
restriction sites to the 39end. The Pis0 vector was purchased from
Addgene Inc. Cambridge, MA, USA (Addgene plasmid 12178)
[34]. Site directed mutagenesis was used to alter the miRNA target
sites using the mouseMitf-39UTR-luciferase clone as a template.
MicroRNA molecules
MicroRNAs used in this study were purchased from Ambion,
Inc. and are the following: hsa-miR-27a (Product ID:PM10939),
hsa-miR-32 (Product ID:PM10124), hsa -miR-101 (Product
ID:PM10537), mmu-miR-124a (Product ID:PM10691), mmu-
miR-137 (Product ID: PM10513), hsa-miR-148a (Product
ID:PM10263), hsa-miR-182. (Product ID:PM11090), Pre-miR-
neg#2 (Cat. no. AM17111), Cy3-labeled Pre-miR Negative
Control#1 (Cat. no. AM17120).
MicroRNA inhibitors
anti-microRNA where purchased from Ambion and are the
following: anti-miR-137 (Product ID: AM10513) and anti-miR-
148 (Product ID: AM10263).
Cell culture conditions
Human embryonic kidney cells (HEK293) were cultured in
DMEM medium with 10% FBS, penicillin-streptomycin (50 U/
ml) and 2 mM glutamine. 501mel melanoma cells were cultured in
RPMI medium with 10% FBS and penicillin-streptomycin (50 U/
ml). MeWo melanoma cells were cultured in DMEM medium
with 7% FBS, penicillin-streptomycin (50 U/ml) and 2 mM
glutamine. Cells were grown at 37uC with 5% CO2.
Co-transfection
DNA and miRNAs were co-transfected into HEK293 and
501mel cells with Lipofectamine 2000 from Invitrogen (Cat
no. 11668-019) in Optimem I + Glutamax-I Reduced Serum
Medium from Invitrogen (Cat.no. 51985), according to the
manufacturers protocol. Cells were grown in 96 well plates. In
each well 10 ng vector DNA, 0.2 ng of Renilla luciferase DNA
and an miRNA at either 0.1 pmol, 0.5 pmol or 1 pmol
concentration were co-transfected. A negative control was
included in all co-transfections. For co-tranfection with the
mutated 39UTR clones we analysed the highest concentration in
each case, or 1 pmol miRNA. miRNA inhibitors were transfected
at concentration of 1 pmol miRNA. Transfected cells were
incubated for 48 hrs. at 37uC with 5% CO2 before luciferase
expression was measured. Experiments were repeated three times
in 6 replicates, except experiments when two different miRNAs
were co-transfected simultaneously which was done only once in
six replicates.
Luciferase measurements
The Dual Luciferase Reporter Assay System from Promega was
used to measure luciferase expression on a Wallac Victor 2 1420
Multilabel counter.
Mutagenesis
Locations of miRNA binding sites were determined using the
mRNA sequence of mouse Mitf 39UTR and are numbered starting
at the first nucleotide after the stop codon. Quikchange Lightning
Site-directed Mutagenesis Kit from Stratagene (Cat.no.#10518)
was used to mutate the miRNA binding sites in the mouse Mitf
39UTR sequence. Primers were designed using the Primerdesign
program from Promega (Table 1). In order to avoid the possibility
that the mutated sequence itself forms a microRNA target, the
corresponding ‘‘new’’ seed region was used to search for predicted
targets of novel small RNAs in TargetscanCustom 4.2. (http://
www.targetscan.org/vert_42/seedmatch.html).
Transfection of miRNAs into MeWo cells
Cells were plated at 1.422610
5 density on 6 well plates. The
following day, 20 pmol miRNA or 20 pmol miRNA together with
20 pmol of the anti-miRNA were transfected in triplicate with
Lipofectamin 2000 and total RNA isolated for qRT-PCR analysis
48 hrs. post transfection. Subsequently, proteins were extracted
and analyzed.
RNA extraction and cDNA synthesis
Total RNA was extracted from MeWo cells using TRIzol
Reagent (Invitrogen), according to the manufacturers protocol
[35]. RNA quantity was measured using Nanodrop Spectropho-
tometer ND-1000 and RNA integrity was determined using
Agilent 2100 Bioanalyzer. RNA Integrity number was above 7.6
in all cases. RNA was treated with DNAseI and purified with the
RNEasy Minelute kit from Qiagen. Purified RNA (1 mgi n1 0ml
reaction) was used for cDNA synthesis with Superscript III RT
(200 U/ml), and anchored Oligo(dT)20 primer according to the
manufacturers protocol. The RNA samples were tested for
absence of inhibitors using the SPUD assay - no inhibitors were
detected [36].
Quantitative reverse transcription PCR
Human MITF mRNA was measured in total RNA samples
extracted from MeWo cells, using the human MITF FAM-labelled
TaqMan Gene Expression Assay (hs01115560) (Applied Biosys-
tems). Samples were measured in triplicate. Two controls were
included, one without RT and the other without template.
Standard conditions for TaqMan reagents were used. The results
were normalized to total RNA (Log250). b-actin was used as a
Mitf and miRNAs
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were analysed using the GenEx Std. 4.4.2. software from MultiD
analyses AB (Sweden).
Western blot
Proteins were isolated from the phenol-ethanol supernatant
after RNA and DNA had been isolated using the Trizol reagent
(Invitrogen), according to the manufacturers protocol [35]. The
proteins were separated on a 10% SDS-PAGE polyacrylamide gel.
The proteins were electroblotted onto a PVDF transfer membrane
(Thermo Scientific). The membrane was immunoblotted over-
night at 4uC with primary antibody, (C5 mouse-anti-Mitf
monoclonal antibody), in Tris-buffered saline with 5% milk. The
C5 mouse-anti-Mitf monoclonal antibody is raised against the N-
terminus of MITF. This antibody detects all isoforms of MITF and
does not differentiate between them. A horse-radish peroxidase
labelled anti-mouse secondary antibody (Jackson) was incubated
with the membrane for 1 hr. after washing with TBST. Signals
were detected with ECL reagent from Thermo Scientific.
Endogenous miRNA expression
Total RNA was isolated from MeWo, 501mel and HEK293
cells as before and samples in triplicate were sent to Exiqon for
analysis using the miRCURY LNA microRNA PCR system. PCR
assays for hsa-miR-137 (MIMAT0000429), hsa-miR-124 (MI-
MAT0000422), hsa-miR-506 (MIMAT0002878), hsa-miR-148a
(MIMAT0000243), hsa-miR-148b (MIMAT0000759) and hsa-
miR-152 (MIMAT0000438) were used to measure endogenous
miRNA expression.
Statistical analysis
T-test analysis (for independent groups) was performed on
results from the luciferase assays, qRT-PCR results from
transfection in MeWo cells and endogenous miRNA expression
analysis.
Results
The Mitf 39UTR sequence and potential microRNA
binding sites
The mouse and human Mitf 39UTR sequences are unusually
long or over 3 kb in length. This is considerably larger than the
average mouse and human 39UTR sequences which are 559 and
826 nucleotides, respectively [37]. The overall conservation of the
Mitf 39UTR sequence in 11 vertebrate species is 36% [38] which is
very high for a non-coding region. This suggests a functional
relevance of the 39UTR sequence of Mitf. Using the TargetScan
program (www.targetscan.org), we identified several miRNA
binding sites located in the most conserved areas of the 39UTR
region. We tested the effects of microRNAs which have conserved
binding sites in the 39UTR region of Mitf, including miR-27a
(located at 229–235 in the mouse Mitf 39UTR sequence), miR-25/
32/92/363/367 (1491–1497), miR-101/144 (3023–3029), miR-
124/506 (1639–1646) and miR-148/152 (1674–1680 and 2931–
2937) (Fig. 1A and 1B). miR-124/506 also has a less conserved
binding site at 548–554, and was therefore also tested in our study.
In addition, the potential binding sites for miR-137 were tested as
the mouse and human Mitf 39UTR sequences both contain two
well conserved miR-137 binding sites located in close proximity to
each other, 137C (2842–2848) and 137D (3061–3067). Two
additional less conserved miR-137 binding sites were found, one
only in the mouse 39UTR, namely 137A (2495–2501) and one
conserved in the mouse and rat 39UTR sequences, 137B (2782–
2788). It has been shown that single miRNAs with multiple
binding sites in a 39UTR sequence have increased effects as
compared to miRNAs with only a single binding site [39,40]. This
is also true when the binding sites are located in close proximity to
each other [41]. In some cases, several different miRNA molecules
can potentially bind to the same binding site. In these cases only
one representative miRNA molecule was chosen to test the
functionality of that specific binding site. If the representative
Table 1. Primers used for mutagenesis.
Primer name Sequence
miR-124 (548-554)F 59-ggcaatttcctggtactcgggcccagacacagtgccc-39
miR-124 (548-554)R 59-gggcactgtgtctgggcccgagtaccaggaaattgcc-39
miR-124 (1639-1646)F 59-gcataccctttcagaatgaagccgggccaaaatctcagcagtctc-39
miR-124 (1639-1646)R 59- gagactgctgagattttggcccggcttcattctgaaagggtatgc-39
miR-137 (2495-2501)F 59-gctgggagaggcaggccccgggcttagaggtgacaacataggg-39
miR-137 (2495-2501)R 59-ccctatgttgtcacctctaagcccggggcctgcctctcccagc-39
miR-137 (2782-2788)F 59-gccaaaaactgtgccccgggcctggtcatacccagagcatgatgcag-39
miR-137 (2782-2788)R 59-ctgcatcatgctctgggtatgaccaggcccggggcacagtttttggc-39
miR-137 (2842-2848)F 59-ggttgtttgtaaacaataaccgggccagaataaacaaaatgcacagg-39
miR-137 (2842-2848)R 59-cctgtgcattttgtttattctggcccggttattgtttacaaacaacc-39
miR-137 (3061-3067)F 59-gccccccgctgttgggtacccgggccctttctgtatggtccgc-39
miR-137 (3061-3067)R 59-gcggaccatacagaaagggcccgggtacccaacagcggggggc-39
miR-148/152 (1674-1680)F 59-cagcagtctcttttggaccagcagcccctgaactgtaactaggag-39
miR-148/152 (1674-1680)R 59-ctcctagttacagttcaggggctgctggtccaaaagagactgctg-39
miR-148/152 (2931-2937)F 59-gttaatatttctgaaaaaaaaccgggccgggagaagttgatgttg-39
miR-148/152 (2931-2937)R 59-caacatcaacttctcccggcccggttttttttcagaaatattaac-39
Mutated bases are bold and underlined.
doi:10.1371/journal.pone.0011574.t001
Mitf and miRNAs
PLoS ONE | www.plosone.org 3 July 2010 | Volume 5 | Issue 7 | e11574Figure 1. Schematic presentation of the mouse Mitf -39UTR sequence. A. The line indicates the 39 UTR region of the mouse Mitf gene,
including the coding region of exon 9. Potential binding sites for miR-27, miR-124/506, miR-25/32/92/363/367, miR-148/152, miR-137 and miR-101/
144 in the mMitf 39UTR sequence are indicated below the line and potential PAS sites above. Positions are based on the mouse Mitf 39UTR sequence
and are numbered starting at the first nucleotide after the stop codon. Black bars: miR-124/506 binding sites, dark grey bars: miR-137 binding sites,
light grey bars: miR-148/152 binding sites, white bars: miR-27, miR-25/32/92/363/367 and miR-101/144. B. The conservation of potential miRNA
Mitf and miRNAs
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that the other potential miRNAs may also be able to regulate Mitf
expression. miR-182 has been shown previously to target the
39UTR of Mitf and was used as a positive control [32].
miR-148/152 affects mMitf RNA in melanoma cells
To test the functionality of the miRNA binding sites, the mouse
Mitf 39UTR sequence was cloned downstream of a luciferase
reporter gene. This vector was then co-transfected into cells
together with single miRNA molecules and effects of the specific
miRNAs on expression determined by measuring luciferase
activity. In 501mel cells, miR-148 had significant effects on
expression of the mouseMitf-39UTR-luciferase reporter (Fig. 2A).
Co-transfection with miR-101 resulted in some downregulation of
the reporter whereas other miRNAs tested did not show
statistically significant effects compared to the mouseMitf-
39UTR-luciferase vector alone. When determining how effective
each miRNA was in our assay, the expression from the vector
when co-transfected with the miRNA was compared to the
expression from the vector alone.
miR-137 and miR-124/506 affect mMitf RNA in HEK293
cells
The luciferase assay experiments were also performed in human
embryonic kidney cells (HEK293), which do not express Mitf at
significant levels. The effects of the miRNAs in HEK293 cells are
different from the effects seen in 501mel melanoma cells. In
HEK293 cells the microRNA miR-137 negatively affected the
mouseMitf-39UTR-luciferase reporter construct, compared to the
reporter construct alone (Fig. 2B). miR-148 affected the reporter
only when transfected at the highest concentration (1pmol)
(Fig. 2B). miR-124, however resulted in significant increase in
reporter gene expression. The other miRNAs tested, miR-27,
miR-32 and miR-101 did not show significant effects on luciferase
expression in this assay (Fig. 2B). This is surprising as the binding
sites for these three miRNAs are very well conserved. All Mitf
39UTR sequences in 11 vertebrate species analysed contain the
miR-27, miR-25/32/92/363/367 and the miR-101/144 binding
sites (Fig. 1B). In addition, seven species contain a conserved
second miR-101/144 binding site. Despite this conservation, these
sites do not seem to be regulated by miRNAs in our assays.
The different results in melanoma cells as compared to
HEK293 cells might be explained by different levels of
endogenous miRNA expression in these cell types. If one of the
miRNAs tested has high endogenous expression in one of the cell
types it would affect the expression of the reporter alone. Adding
more of the miRNA would presumably not make a major
difference. Thus, the effects of the transfected miRNA would be
masked by the endogenous expression of the miRNA.
Many different miRNAs can bind simultaneously to a specific
39UTR sequence and affect expression. Thus, we tested if
transfecting two different miRNAs simultaneously would reveal
additive effects. The results are compared to expression by the
mouseMitf-39UTR-luciferase reporter alone. When miR-137 was
combined with other miRNAs, the effects were always equal to the
effects observed with miR-137 alone. Also, when miR-124 was
combined with other miRNAs, the effects were always equal to the
effects observed with miR-124 alone. When miR-124 and miR-
137 were combined, the same effect was observed as when miR-
137 was transfected alone (Fig. 2C). Other combinations of two
miRNAs did not show increased effects. Thus, we detect no
cooperation among the miRNA molecules with respect to effects
on Mitf.
Roles of individual miRNA target sites revealed through
mutagenesis
To confirm that the miRNAs which show effects on the
mouseMitf-39UTR-luciferase reporter are in fact operating
through the predicted potential binding sites, the miRNA binding
sites were mutated in the mouseMitf-39UTR-luciferase vector and
the vector then co-transfected into cells together with the specific
miRNAs, as before. miRNAs bind to their 39UTR binding site
through a seed region located at position 2–7 or 2–8 in the mature
miRNA sequence [27,42]. We mutated all 7 bases in the 39UTR
binding site matching the seed region of the mature miRNAs in
order to abolish completely the binding of the miRNA. In the case
of one of the miR-148 binding site, 148/152A, only 4 bases were
mutated as a clone with the fully mutated binding site was not
generated successfully. The mutations are shown in Fig. 1C and
the primers used for mutagenesis in Table 1.
Role of the miR-148/152 target sites. There are two target
sites for miR-148/152 in the mouse Mitf 39UTR sequence. Each
of the two sites were mutated, 148/152A located at 1674–1680,
and 148/152B located at 2931–2937 (Fig 1A). In these
experiments, we define the expression level of the vector alone
as 100%. When determining how effective each mutation was in
our assays, expression of luciferase from the mutated vector alone
was compared to expression from the mutated vector when co-
transfected with the appropriate miRNA. When both binding sites
were functional miR-148 downregulated reporter gene expression
to 50–60% compared to expression from the vector alone in
501mel cells (p=0.0140) (Fig. 3A). When the 148/152A binding
site was mutated, miR-148 downregulated reporter gene
expression to 47% (p=0.0049). However, when the 148/152B
binding site was mutated, miR-148 was no longer able to
downregulate reporter gene expression (p=0.3929). When both
binding sites were mutated, reporter gene expression was the same
as when 148/152B was mutated (118%, p=0.4918). These results
indicate that miR-148 is able to downregulate Mitf expression by
binding to the 148/152B binding site.
Role of the miR-137 target sites. The four target sites for
miR-137 in the Mitf 39UTR sequence, 137A (2495–2501), 137B
(2782–2788), 137C (2842–2848) and 137D (3061–3067) were
mutated seperatly. In addition, a double mutant was created
where the most conserved sites 137C and 137D were changed
simultaneously, a triple mutant with 137B, 137C and 137D
mutated and a mutant where all four potential binding sites were
changed (Fig. 1C). The mutated mouseMitf-39UTR-luciferase
constructs were co-transfected together with the miRNAs in
HEK293 cells. When all the miR-137 binding sites are functional,
miR-137 reduced expression from the luciferase reporter to only
10% (p=0.0015) compared to the vector alone (Fig. 3B).
When miR-137 was co-transfected with a reporter construct
containing the mutant site 137A, expression from the luciferase
reporter was 7% compared to the vector alone (p,0.0001). This is
similar reduction as was seen with the wild type construct,
binding sites in the Mitf 39UTR sequence. Dots represent a conserved base, short lines represent absence of a sequence at this location. C. Mutations
made in the Mitf 39UTR sequence. The wild type mouse Mitf mRNA sequence is shown with potential binding sites indicated in red. The mature
miRNA sequence and potential binding between the miRNA seed region to the 39UTR sequence are shown and mutated bases are indicated above
the mRNA sequence.
doi:10.1371/journal.pone.0011574.g001
Mitf and miRNAs
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(Fig. 3B). Mutating the 137B site resulted in 16% expression
(p,0.0001) which is a little less reduction than was seen when all
the potential binding sites were functional. When the more
conserved site 137C was mutated, expression from the mouseMitf-
39UTR-luciferase reporter was reduced to 19% (p=0.0001)
(Fig. 3B), indicating a functional role of miR-137C. Mutating
the other well conserved binding site 137D resulted in reduction to
23% expression (p=0.0001) of the mutated mouseMitf-39UTR-
luciferase reporter (Fig. 3B), again indicating a functional target
site. When the two best conserved binding sites (137C and 137D)
were simultaneously mutated, reporter expression was 32%
(p=0.0001) compared to expression from the mutated vector
alone, suggesting that sites C and D play a major role in the
response to miR-137. Surprisingly, when miR-137 was co-
transfected with a reporter construct lacking the 39UTR sequence
of Mitf, miR-137 downregulated luciferase expression to 27%
(Fig. 3B). This suggests that the luciferase vector has binding sites
for miR-137. Indeed, our search for miR-137 binding sites in the
luciferase gene itself resulted in 3 matching sequences. There are
reports showing that binding sites within the coding regions of
genes can result in effects on gene expression [43]. It is also
possible that the miR-137 is affecting other components (genes/
transcripts) that are involved in the transcription of the luciferase
gene. Thus, when sites 137C and 137D were mutated simulta-
neously, the expression of the reporter was reduced to 32% which
is very similar to the level of expression when all miR-137 binding
sites are funcional (27%), suggesting that all the effects of miR-137
on the mouseMitf-39UTR-luciferase are mediated through these
two sites. When three or all four miR-137 binding sites were
mutated simultaneously, the mutated vector alone was unable to
express the luciferase gene (data not shown). One possible
explanation for this might be that the structure of the 39UTR is
altered when 21 or 28 conserved bases are mutated, leading to
reduced stability or effects on translation of the message. miR-137
has previously been shown to target Mitf by acting through the best
conserved miR-137 target sites [31]. However, in that study, only
a portion of the Mitf 39UTR sequence was used in the analysis
[31]. In our analysis, however, the entire 39UTR sequence from
mouse Mitf (over 3 kb) was used to analyse the role of the binding
sites. This more closely resembles the endogenous situation. Our
results therefore confirm the role of miR-137 in regulating Mitf
expression.
Role of the miR-124/506 target sites. There are two
binding sites for miR-124/506 in the mouse Mitf 39UTR
sequence. Site 124/506A is located at 548-554 and site 124/
506B at 1639-1646 in the mMitf 39UTR sequence. When both
binding sites are functional, miR-124 positively affects luciferase
expression up to 3 fold compared to expression from the vector
alone in HEK293 cells (p=0.0086) (Fig. 3C). We mutated each
target site alone and also made a double mutation changing both
sites. When the 124/506A binding site was mutated, miR-124 no
longer affected expression of the reporter gene. The expression
was only 81% compared to 315% in the vector alone (P=0.1376).
When the 124/506B binding site was mutated, miR-124 still
upregulated lucifease expression to 240% (p=0.0030). When both
binding sites were mutated, miR-124 did not result in increased
expression of the luciferase reporter, at least not as effectively as
when both potential binding sites were functional (146%
expression, p=0.1864). These results suggest that miR-124 leads
to positive effects on the Mitf mRNA by binding to the 124/506A
binding site. At present, it is not clear how miR-124 mediates this
upregulation. The effects of miR-506, that binds to the same target
site, were not tested.
miR-148 and miR-137 affect expression of the
endogenous MITF
In order to test if these miRNAs affect the level of endogenous
MITF mRNA in melanoma cells, we used qRT-PCR to determine
MITF mRNA expression after transfecting MeWo melanoma cells
with the miRNAs miR-124, miR-137 and miR-148. MeWo cells
express less MITF than the 501mel cells used previously.
Therefore, the difference in expression upon treatment was more
easily detected with the amount of miRNA used. The results,
normalized to total RNA, are shown in Fig. 4A and confirm our
previous findings. When miR-137 was transfected into MeWo
cells, the level of MITF mRNA was reduced to 68% (Cp value
22.3, p=0.0069) compared to 100% in untreated cells (No-miR,
Cp value 21.7). Similarily, when miR-148 was transfected into
these cells, MITF mRNA level was reduced to 48% (Cp value
22.8, p=0.0051) compared to untreated cells. Simultaneous
transfection with miR-137 and miR-148 did not result in further
effects on MITF expression as it reduced expression to 67% (Cp
value 22.3, p=0.0051), which is similar to the reduction seen with
miR-137 alone (Fig. 4A). Thus, these miRNAs do not seem to
work synergistically in downregulating MITF.
Similar to what we observed using the luciferase-reporter assay,
miR-124 was able to upregulate MITF expression in the MeWo
cells. The expression was increased to 122% (Cp value 21.5)
compared to untreated cells; however, this difference is not
statistically significant (p=0.2228). The same experiment was
performed once in 501mel cells, the only signifant downregulation
was by miR-137 when compared to transfection with a scramble
miRNA (data not shown). These results show that the miR-137
and miR-148 have the same effects on expression of the
endogenous MITF gene as seen using the luciferase reporter
assay. The effects of miRNAs on MITF protein level were also
tested in MeWo cells and confirmed our previous findings (Fig. 4B).
When the cells were transfected with either miR-137, miR-148 or
simultaneously with both miR-137 and miR-148, MITF protein
levels were reduced. Also, when miR-124 was transfected, higher
MITF protein levels were observed (Fig. 4B).
In order to test the specificity of the miRNAs, we used specific
anti-miRNAs to inhibit the effects of the miRNAs used in our
experiments. Consistent with previous results, cells simultaneously
transfected with the luciferase vector construct, the miR-148 and
the anti-miR-148 showed that the anti-miR148 molecule effec-
tively inhibited the effects of miR-148 (Fig. 5A). Similarly, the
effects of miR-137 and miR-148 on endogenous MITF mRNAs
are inhibited when MeWo cells were co-transfected with anti-
miRNAs (Fig. 5B). These results further verifies that the effects on
Mitf mRNA are specific to these microRNAs.
Figure 2. Effects of microRNAs on the Mitf-39UTR-luciferase reporter. A. Effects of miRNAs on the mouseMitf-39UTR-luciferase reporter in
501melanoma cells. Three concentrations of miRNAs were tested: 0.1 pmol, 0.5 pmol and 1 pmol. Results in all panels are presented as mean values
6SD. Difference between the mouseMitf- 39UTR-luciferase vector with and without co-transfected miRNA was considered statistically significant
when p,0.05, shown with an asterisk (T-test, 95% confidence level). P-values are presented in Table S1. B. Effects of miRNAs on the mouseMitf-
39UTR-luciferase vector in HEK293 cells. Three concentrations of miRNAs were tested: 0.1 pmol, 0.5 pmol and 1 pmol. C. Effects of miRNAs when
transfected in combination with another miRNA on the reporter. Concentration of each miRNA is 0.5 pmol.
doi:10.1371/journal.pone.0011574.g002
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The expression of miRNAs 137, 124, 506, 148a, 148b and 152
was determined in the HEK293, 501mel and MeWo cell lines.
The expression of the miRNAs was measured using the MiRcury
LNA Universal RT microRNA PCR method. An RNA pool from
20 different tissues was used as a positive control and the results
were normalized to the expression of miR-16 and miR-103. Cp
values (crossing point) are shown in Table 2.
miR-148 and miR-152. The microRNAs miR-148a and
miR-148b have similar expression levels in all the cell types tested.
Expression in the melanoma cell lines 501mel and MeWo was
around 1.5 fold less than expression in HEK293 cells (Fig. 6).
Higher endogenous expression in HEK293 cells might explain
why transfected miR-148 had no effect on reporter gene
expression in HEK293 cells, except at the highest concentration.
miR-148 affected reporter gene expression more significantly in
Figure 3. Mutating miRNA binding sites affects the Mitf mRNA. A. Effects of miR-148 on the mouseMitf-39UTR-luciferase reporter when the
potential binding sites are mutated. Results in all panels are presented as mean values 6SD. Difference between the appropriate vector (labeled on
the X-axis) with and without co-transfected miRNA was considered statistically significant when p,0.05, shown with an asterisk (T-test, 95%
confidence level). P-values are presented in Table S1. B. Effects of miR-137 on the mouseMitf-39UTR-luciferase reporter when the potential binding
sites are mutated. C. Effects of miR-124 on the mouseMitf-39UTR-luciferase reporter when the potential binding sites are mutated.
doi:10.1371/journal.pone.0011574.g003
Figure 4. Effects of miRNAs on endogenous MITF. A. Expression of human MITF mRNA in MeWo cells transfected with miR-124, miR-137, miR-
148 or miR-137 and miR-148 combined. The figure shows average expression levels of three replicates for each sample relative to untreated cells (No-
miR). Negative control is a scramble miRNA sequence (scramble). Statistically significant difference between untreated cells and treated cells are
shown with an asterisk (T-test, 95% confidence level). P-values are: Scramble =0.0396; miR-124=0.2228; miR-137=0.0069; miR-148=0.0051; miR-
137+148=0.0051. B. Western blot analysis on MITF protein levels in MeWo cells, when transfected with miR-124, miR-137, miR-148 or miR-137 and
miR-148 combined.
doi:10.1371/journal.pone.0011574.g004
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than in HEK293 cells and was much lower then the expression of
miR-148a and miR-148b in all cell types (see Table 2). Low
expression of miR-148a, 148b and 152 in the melanoma cell lines
is therefore consistent with the relatively high level of MITF
expression in these cells.
miR-137. Endogenous miR-137 was only detected in MeWo
cells, not in HEK293, 501mel or the positive control. Expression
in the MeWo cells, although at rather low levels (average Cp value
34.7 compared to the controls (miR-16 and 103) at 25.9 and 27.8
respectively), indicates possible involvement in regulating the
endogenous levels of MITF in this cell type. MITF is expressed in
MeWo cells but at a lower level than in 501mel cells which is
consistent with the expression of miR-137 in MeWo cells and its
absence in 501mel cells. miR-137 affected reporter gene
expression in HEK293 cells, which is in line with the absence of
endogenous miR-137 in this cell type. It is unclear why transfected
miR-137 did not affect reporter gene expression in 501mel cells
where endogenous miR-137 was not detected. The absence of
miR-137 in 501mel cells might be explained by mutations in the
miR-137 gene itself as has been shown to be the case in other
melanoma cells [31], thus allowing high levels of MITF expression.
miR-124 and miR-506. The level of miR-124 expression was
considered to be too low to be detected in all cell types. We
Figure 5. Inhibiting the miRNAs blocks their effect. A. Co-transfection of anti-miR-148 and miR-148 simultaneously with the Mitf-39UTR-
luciferase vector inhibits the effect of miR-148. Results are presented as mean values 6SD. Expression levels were compared to a sample where no
microRNAs were added (No-miR) and were considered statistically significant when p,0.05, shown with an asterisk (T-test, 95% confidence level). The
p-values are; miR-neg =0.14 miR-148=0.007, miR-148+anti-miR-148=0.119. B. Transfecting miRNAs and anti-miRNAs blocked the effect of the
miRNAs on endogenous human MITF mRNA levels in MeWo cells. P-values when compared to the no-miR sample are: Neg control =0.064, miR-
137=0.006, miR-137 + anti-miR-137=0.854, miR-148=0.004, miR-148 + anti-miR-148=0.632.
doi:10.1371/journal.pone.0011574.g005
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expression of miR-124 in our samples. miR-506 was detected in
501mel and MeWo cells. The expression level was higher in
MeWo cells (Cp value 32.9) compared to 501mel cells (Cp value
34.7). Lower expression in 501mel might be a factor allowing a
high level of MITF expression in this melanoma cell type.
Discussion
We have tested the role of six different miRNAs with conserved
potential binding sites in the Mitf 39UTR sequence for their ability
to affect Mitf mRNA expression. We show that miR-137 and miR-
148 negatively affect Mitf mRNA in melanoma cells through
conserved binding sites in the 39UTR sequence. Other miRNAs
tested, miR-27 and miR-25/32/92/363/367 have highly con-
served binding sites but did not have an effect on reporter gene
expression in HEK293 or 501mel cells. The microRNA miR-101
has a highly conserved binding site but did not affect reporter gene
expression in HEK293 cells. However in 501mel cells, miR-101
downregulated reporter gene expression at the two highest
concentrations used suggesting that it may play a role in
melanocytes or melanoma cells.
The roles of miR-137 and miR-148 were analysed further by
mutating the binding sites in the mouseMitf-39UTR-luciferase
reporter construct. The results of this analysis suggest direct effects
on the Mitf mRNA. When the 148/152B binding sites were
mutated, the effects of miR-148 were eliminated. When the most
conserved binding sites for miR-137 (137C and D) were mutated,
the effects of miR-137 were eliminated. None of the miR-137-
mutations restore luciferase expression to the level observed with
the negative control. This might indicate that all the miR-137
binding sites contribute to the regulation of Mitf. However, it
should be noted that miR-137 can target the luciferase construct
lacking the 39UTR sequence such that in the presence of miR-137,
luciferase expression cannot reach the same level of expression as
is seen with the negative control (miR-neg#2).
The effects of the miRNAs were further confirmed by
transfecting the microRNAs into MeWo melanoma cells and then
measuring the endogenous MITF mRNA and protein levels. miR-
137 and miR-148 both led to reduced levels of MITF mRNA and
protein. Simultaneous transfection with anti-miR-148 blocked the
effect of miR-148 in both the luciferase reporter assays and on the
endogenous MITF mRNA. Transfection with anti-miR-137
similarly blocked the effects of miR-137 on the endogenous MITF
mRNA (Fig. 5B). miR-137 did not significantly affect the luciferase
reporter in melanoma cells. However, simultaneous transfection of
anti-miR-137 and miR-137 with the Mitf-39UTR luciferase in
MeWo cells blocked the effect of miR-137 (data not shown).
Combining both miR-137 and miR-148 did not result in added
effects on endogenous MITF mRNA levels. Possible explanations
for this might be that the maximum effects are reached with one of
Table 2. Cp values for determining endogenous miRNA
expression.
miRNA HEK293 501mel MeWo
Positive
contr.
miR-137 ND (1/9) ND (0/9) 34.69 (7/9) 37.39 (1/3)
miR-124 34.37 (9/9) 34.73 (5/9) 35.09 (2/9) 32.68 (3/3)
miR-506 35.19 (2/9) 34.73 (3/9) 32.87 (9/9) ND (0/9)
miR-148a 27.90 (9/9) 28.29 (9/9) 28.82 (9/9) 33.12 (3/3)
miR-148b 28.37 (9/9) 28.65 (9/9) 29.37 (9/9) 35.19 (1/3)
miR-152 34.08 (9/9) 35.12 (9/9) 34.26 (9/9) 35.05 (2/3)
miR-16 contr. 26.19 (9/9) 25.72 (9/9) 25.92 (9/9) 31.83 (3/3)
miR-103 contr. 27.07 (9/9) 26.76 (9/9) 27.81 (9/9) 33.09 (3/3)
Cp values for average normalised values are shown for each miRNA tested in
HEK293, 501mel and MeWo cells as well as the positive control. Each assay was
preformed in triplicate for three RNA samples from each cell type. The number
of samples that each miRNA was detected in, is shown in parenthesis. ND = not
detected.
doi:10.1371/journal.pone.0011574.t002
Figure 6. Endogenous miRNA expression. Expression of endogenous miRNAs miR-148a, miR-148b and miR-152 in HEK293, 501mel and MeWo
cells. The figure shows average expression levels of three replicates for each sample relative to HEK293 cells. Expression was normalized to miR-16
and miR-103. Statistically significant levels of expression in MeWo and 501mel compared to HEK293 (p,0.05) are shown with an asterisk. P-values are:
miR-148a expression in 501mel =0.0940 and in MeWo =0.0148. miR-148b expression in 501mel =0.0023 and in MeWo =0.0065. miR-152 expression
in 501mel =0.0054 and in MeWo= 0.9316.
doi:10.1371/journal.pone.0011574.g006
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Another explanation for the lack of additive effects is that the
miRNAs might not be able to bind simultaneously to the 39UTR
sequences. The 137C, 137D and 148/152B binding sites are all
located in close proximity to each other in the Mitf-39UTR
sequence (Fig. 1A). Accessibility might be limited by one of the
miRNAs. A third possibility is that specific binding proteins block
the other sites when one is occupied. Specific RNA binding
proteins have been show to block the binding of miRNAs to the
MITF mRNA [44]. The fact that miR-137 has an effect in MeWo
cells (q-RT-PCR) and not in 501mel cells might be due to the fact
that MITF mRNA levels are higher in 501mel cells than in MeWo
cells. Thus, more miR-137 might be needed in 501mel cells then
in MeWo cells. The effects of miR-137 and miR-148 when
transfected seperatly, are blocked when the cells are transfected
with miR-137 and miR-148 inhibitors. miR-124 resulted in
increased luciferase expression as seen using the reporter gene
construct in HEK293 cells. Furthermore, we observed upregula-
tion of the endogenous MITF in MeWo cells at both mRNA and
protein levels; the upregulation of MITF mRNA was not
statistically significant. The effects of miR-124 might be an artifact
of the reporter system. The effects on endogenous MITF could not
be measured in HEK293 cells as there is no endogenous MITF
expression in those cells.
As mentioned earlier, miR-137 has previously been shown to
target MITF in melanoma cells [31]. Interestingly, searching for
miR-137 binding sites within the Mitf 39UTR sequence of 11
vertebrate species revealed that all species have at least two miR-
137 binding sites and some species have three or four binding sites.
All species contain either 137C or 137D and nine contain them
both (data not shown). miR-137 expression has been shown to be
affected in cancer. It is silenced by DNA methylation in colorectal
cancer [45] and oral carcinogenesis [46], suggesting tumor
suppressor abilities. In addition, both miR-137 and miR-124
induced differentiation of adult mouse neural stem cells and were
able to induce cell cycle arrest of glioblastoma multiforme cells
[47]. Upregulation of miR-137 in lymph node metastasis in colon
cancer has also been observed [48].
The 39UTR sequences of Mitf in 11 vertebrate species all
contain the two conserved miR-148/152 binding sites. In six
vertebrate species there is an additional conserved binding site
(data not shown). It has not been shown previously that miR-148
and/or miR-152 can target Mitf. However, both miRNAs have
been shown to be downregulated in melanoma cells [30].
Microarray analysis revealed that miR-148b is downregulated in
early melanoma progression, although it was not confirmed using
qRT-PCR [30]. Similarly, miR-152 was shown to be downreg-
ulated in a highly invasive melanoma cell line (Mel Im) [30]. Other
studies have suggested that miR-148 and miR-152 can play a role
as tumor suppressors. miR-148 expression has been shown to be
downregulated in tissue samples from undifferentiated gastric
cancer compared to normal tissue [49]. Similarly, hypermethyla-
tion of the miR-148, 124a3 and miR-152 genes was found in 34-
86% of primary human breast cancer specimens [50].
The binding sites for microRNAs miR-124/506 are very well
conserved in the Mitf 39UTR sequence. Ten vertebrate species
contain both miR-124/506 binding site; the Loxodonta africana
sequence only contains 124/506B. It has not been shown
previously that miR-124 and/or miR-506 can affect Mitf mRNA.
However, miR-506 was shown to be upregulated in early
melanoma progression and downregulated later in metastatic
melanoma [30] and may therefore play an important role in this
cell type. miR-124 is predominantly expressed in the brain,
specifically in differentiating and mature neurons [51,52,53]. miR-
124 is interesting considering its expression in the retina [54], as
Mitf plays an important role in eye development. Mitf is expressed
in the retina early in development and is later downregulated in
this tissue [55,56,57]. The mechanisms that mediate this
downregulation have not been described and may involve miR-
124. However, our results show upregulation by miR-124 in
melanoma cells, rather than downregulation. The possible role of
miR-124 in regulating the expression of Mitf during eye
development needs to be tested further. Although miRNAs are
better known for downregulating target genes, there have been
reports on effects through upregulation by miRNAs by binding to
their promoter region [58,59]. However, this is unlikely to play a
role in regulating Mitf mRNA through effects on the 39UTR since
our reporter construct only contained 39UTR sequences.
It has been shown that two thirds of genes targeted by miRNA
have alternative 39UTRs. The microRNAs miR-137 and miR-148
have many other potential target genes according to online
prediction programs (Targetscan). In humans, miR-137 has 857
conserved targets, with a total of 949 conserved sites and 120
poorly conserved sites. miR-148 has 536 conserved targets, with a
total of 581 conserved sites and 134 poorly conserved sites. Of
these potential target genes, 66 are common targets of both miR-
137 and miR-148. It is therefore unlikely that these miRNAs
exclusively affect Mitf expression.
As miRNA binding sites are often located close to polyadenyl-
ation signals (PAS) [60], shortening of the 39UTRs may lead to loss
of miRNA binding sequences and thus loss of microRNA-
mediated regulation. The mouse Mitf 39UTR sequence contains
twelve potential PAS sequences (two are AAUAAA, four
AUUAAA, four AAGAAA and two UAUAAA, there is no
AGUAAA sequence). Comparing these potential PAS sites in the
39UTR sequences of Mitf from 11 vertebrate species revealed a
well conserved PAS located at 2837-2842, adjacent to the miR-
137 C binding site (Fig. 1A). Ten species contain a PAS at this
location. The PAS located closest to the 39end is conserved in all
species and represents the signal for the longest mRNA version.
Several other PAS’s are well conserved whereas others are less
conserved. miRNAs can have an impact on cancer progression in
several ways, including loss of expression of a tumor-suppressor
miRNA gene and over-activation of an oncogenic miRNA. Loss of
miRNA binding sites in 39UTR sequences of the target genes
caused by mutations or translocations are also possible. Shortening
of the 39UTR sequence, and therefore loss of miRNA binding
sites, can lead to oncogenic activation [61]. The conservation of
several of the alternative polyadenylation signals found in the
39UTR sequences of Mitf suggests their significance. Thus, Mitf
might be able to evade miRNA-mediated regulation using the
alternative polyadenylation sites, thus leading to a shorter
transcript lacking the miRNA binding sequences. It was recently
shown that MITF mRNAs with shorter 39UTR sequences are
more abundant in melanoma cell lines than transcripts with full-
length 39UTR sequences [44]. In this case the miR-340 is involved
in regulating the shorter transcript and, interestingly, the RNA
binding protein CRD-BP prevents binding of the miRNA. Thus,
in the case of MITF, microRNAs do not act alone in mediating
regulation through the 39UTR sequences. Interestingly, the MITF
protein has been shown to bind to the promoter of miR-148b that
is shown there to have functional target site within the Mitf 39UTR
sequence [62]. This indicates a possible negative feedback loop
where higher amounts of MITF would lead to more miR-148
expression which in turn adjusts MITF protein at desirable levels.
It is clear that miRNA function is diverse and its role in cancer
and other disease is complex. Some miRNAs seem to have a
tissue-specific function like miR-124 in neurons wheras other
Mitf and miRNAs
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types and may therefore be regulated by different miRNAs in the
different tissues. In melanoma cells, Mitf is regulated by miR-137
and miR-148/152. As MITF is a lineage survival oncogene in
melanoma [23] whose expression needs to be maintained at a
certain level, it is likely that these miRNAs play an important role
in regulating MITF mRNA levels in this cell type. Dysregulation of
these microRNAs, or loss of the binding sites in the 39UTR, might
lead to increased expression of Mitf, thus leading to differentiation
and cell-cycle arrest. As the miRNAs involved may have
significant therapeutic potential, it will be important to character-
ize this regulation in more detail in further studies.
Supporting Information
Table S1 P-values for data presented in Figures 2 and 3.
Found at: doi:10.1371/journal.pone.0011574.s001 (0.02 MB
PDF)
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